Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMD14 | O00487 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.58 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.56 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | KDM4A | O75164 | 1/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.45 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.45 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.45 |
| ▸ | CDK1 | P06493 | 2/20 | 0.45 |
| ▸ | CSF1R | P07333 | 2/20 | 0.45 |
| ▸ | CDK2 | P24941 | 2/20 | 0.45 |
| ▸ | FLT4 | P35916 | 2/20 | 0.45 |
| ▸ | CLK2 | P49760 | 2/20 | 0.45 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.45 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.45 |
| ▸ | STK3 | Q13188 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL69886 | 0.86 | PSMD14 (0.73) | PSMD14KDM4ESLC40A1MAP2K1L3MBTL1 | |
| SCHEMBL19642874 | 0.83 | PSMD14 (0.69) | PSMD14KDM4ESLC40A1MAP2K1L3MBTL1 | |
| SCHEMBL10383135 | 0.83 | KDM4E (0.78) | PSMD14KDM4ESLC40A1MAP2K1L3MBTL1 | |
| SCHEMBL31424218 | 0.83 | KDM4E (0.78) | PSMD14KDM4ESLC40A1MAP2K1L3MBTL1 | |
| SCHEMBL2379491 | 0.83 | L3MBTL1 (0.49) | PSMD14KDM4ESLC40A1L3MBTL1RAB9A | |
| SCHEMBL22492328 | 0.82 | PSMD14 (0.64) | PSMD14KDM4ESLC40A1MAP2K1L3MBTL1 | |
| SCHEMBL7377364 | 0.82 | PSMD14 (0.68) | PSMD14KDM4ESLC40A1MAP2K1L3MBTL1 | |
| SCHEMBL11973493 | 0.82 | PSMD14 (0.68) | PSMD14KDM4ESLC40A1MAP2K1L3MBTL1 | |
| SCHEMBL7654796 | 0.82 | PSMD14 (0.68) | PSMD14KDM4ESLC40A1MAP2K1L3MBTL1 | |
| SCHEMBL19642938 | 0.82 | PSMD14 (0.68) | PSMD14KDM4ESLC40A1MAP2K1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213114-A1 | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2022-07-07 | — | — | US | disclosed |
| US-20220213114-A1 | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2022-07-07 | — | — | US | disclosed |
| US-11312723-B2 | Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases | THE ROCKEFELLER UNIVERSITY (US) | 2022-04-26 | — | — | US | disclosed |
| US-11312723-B2 | Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases | THE ROCKEFELLER UNIVERSITY (US) | 2022-04-26 | — | — | US | disclosed |
| US-20200369677-A1 | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2020-11-26 | — | — | US | disclosed |
| US-20200369677-A1 | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2020-11-26 | — | — | US | disclosed |
| EP-3716972-A1 | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | The Rockefeller University (US) | 2020-10-07 | — | — | EP | disclosed |
| CN-111670034-A | Pyranopyrazoles and pyrazolopyridines immunomodulators for the treatment of autoimmune diseases | 洛克菲勒大学 | 2020-09-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369677-A1 | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | TFPI, TFPI2, SERPINC1 | PSMD14 2382/4885KDM4E 3175/4885SLC40A1 3092/4885 |
| US-11312723-B2 | Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases | TFPI, TFPI2, SERPINC1 | PSMD14 2382/4885KDM4E 3175/4885SLC40A1 3092/4885 |
| US-20220213114-A1 | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | TFPI, TFPI2, SERPINC1 | PSMD14 2382/4885KDM4E 3175/4885SLC40A1 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.